Analysis updated on Nov. 6, 2026 (UTC) · Alpha · vs marketSwitch to Total · OTC
Our AI scores Biocorrx Inc. every trading day against every stock it covers. Create a free account and follow it to see its rating and price target.
Biocorrx Inc. is a small-cap company with a market capitalization of $6M.
For BICX, the Spearman rank correlation between our 90-day forecasts and the returns that followed is -10.0%, measured on 357 forecast dates between 2022-08-19 and 2026-08-07 on this stock's own recent history. A rank correlation runs from -100% to +100%: it measures whether higher forecasts were followed by higher returns, and a value near zero or below means the model has shown little skill on this stock. On the 30-day forecasts the same correlation is -16.0%, measured on 400 forecast dates between 2022-08-19 and 2026-10-07. Across our coverage, the out-of-sample test on 4629 stocks from 2025-01-06 to 2026-08-04 produced a positive net return in 92.9% of rebalance periods (factor-neutral book, net of estimated costs). Full backtest report
Expected return relative to the market over the horizon: a positive alpha means the model expects the stock to beat the market, whatever the market does. Ratings: strong buy ≥ +3.1%, buy ≥ +1.5%, sell < -0.5%, strong sell < -1.8% (top 15%, next 20%, middle 30%, next 20%, bottom 15% of the 2026-11-06 signals)
A free account shows the exact forecast, rating and rank of 3 tickers you follow, BICX included.
90D Alpha forecasts of every company scored, cut into five relative ratings at the 15th, 35th, 65th and 85th percentiles (dashed lines).
Trailing twelve months. The industry median and the rank (1 = highest) are taken over the Services-Specialty Outpatient Facilities, NEC peers listed below that report each metric.
| Metric | BICX | Rank |
|---|---|---|
| Market Cap | $6M | – |
| EPS | $-0.15 | – |
| Revenue/Share | $0.03 | – |
| Metric | BICX | Rank |
|---|---|---|
| ROA | -165.7% | – |
| ROIC | 70.5% | – |
| Gross Margin | 34.6% | – |
| Operating Margin | -623.1% | – |
| Net Margin | -401.9% | – |
| EBT Margin | -399.4% | – |
| Tax Rate | 0.0% | – |
| Metric | BICX | Rank |
|---|---|---|
| Current Ratio | 0.07x | – |
| Quick Ratio | 0.07x | – |
| Interest Coverage | -48.8x | – |
| Working Capital | -$8M | – |
| Metric | BICX | Rank |
|---|---|---|
| Operating Cash Flow | -$2M | – |
| Metric | BICX | Rank |
|---|---|---|
| Asset Turnover | 0.41x | – |
| Receivables Turnover | 11.6x | – |
| Inventory Turnover | 3.3x | – |
| Days Sales Outstanding | 31 days | – |
| Days Inventory | 111 days | – |
| Payables Period | 11308 days | – |
| Cash Conversion Cycle | -11166 days | – |
| Metric | BICX | Rank |
|---|---|---|
| Total Revenue | $790K | – |
| Operating Income | -$5M | – |
| Net Income | -$3M | – |
| R&D Expense | $2M | – |
| SG&A Expense | $3M | – |
| Cost of Goods Sold | $140K | – |
| Metric | BICX | Rank |
|---|---|---|
| Shares Outstanding | 30M | – |
| Total Current Assets | $620K | 32.6% of assets |
| Cash & Short-term Investments | $20K | 1.1% of assets |
| Accounts Receivable | $70K | 3.7% of assets |
| Inventory | $40K | 2.1% of assets |
| Total Liabilities | $14M | |
| Short-term Debt | $4M |
Companies classified under the same SEC industry code as Biocorrx Inc. (Services-Specialty Outpatient Facilities, NEC): 4 common-stock issuers with a forecast this week, one row per issuer, largest first. This is a classification match, not a curated list of competitors.
Reveal all forecasts · See exact % predictions for all competitors
Sign up freeRevenue of $635,224 for Q3 2025, compared to $0 for Q3 2024, driven primarily by LUCEMYRA(R) supply and distribution sales under BioCorRx Pharmaceuticals Inc. Revenues in the period are material and ...
ANAHEIM, CA - January 14, 2026 (NEWMEDIAWIRE) - BioCorRx Inc. (OTCID: BICX) (the "Company"), a developer and provider of innovative treatment programs for substance abuse and related disorders, today ...
ANAHEIM, CA - (NewMediaWire) - April 03, 2024 - BioCorRx Inc. (OTCQB: BICX) (the “Company”), a developer of innovative treatment programs for substance use and related disorders, today announced that ...
Our AI scores Biocorrx Inc. every trading day against every stock it covers. Create a free account and follow it to see its rating and price target.
For BICX, the Spearman rank correlation between our 90-day forecasts and the returns that followed is -10.0%, measured on 357 forecast dates between 2022-08-19 and 2026-08-07 on this stock's own recent history. A rank correlation runs from -100% to +100%: it measures whether higher forecasts were followed by higher returns, and a value near zero or below means the model has shown little skill on this stock. On the 30-day forecasts the same correlation is -16.0%, measured on 400 forecast dates between 2022-08-19 and 2026-10-07. Across our coverage, the out-of-sample test on 4629 stocks from 2025-01-06 to 2026-08-04 produced a positive net return in 92.9% of rebalance periods (factor-neutral book, net of estimated costs). Full backtest report
Biocorrx Inc. forecasts are refreshed on trading days as the daily model run completes. The forecast on this page was produced on Nov. 6, 2026.
4 issuers in our coverage, BICX included, share the SEC industry code Services-Specialty Outpatient Facilities, NEC. The largest are: Concentra Group Holdings Parent, Inc. (CON), Acadia Healthcare Company, Inc. (ACHC), Elite Health Systems Inc. (EHSI).
This analysis is generated automatically using our proprietary AI systems and should not be considered personalized investment advice. Past performance does not guarantee future results. Always conduct your own research and consider consulting a financial advisor before making investment decisions.
Signals, companies, plans: answered from live data.
I read Intratio's daily model signals, company data and your account to answer in seconds, in your language.
